文献速递消化内镜消化道肿瘤与早癌

粪便免疫化学试验阳性无症状平均风险人群结肠镜腺瘤检出率的汇总分析:系统综述与Meta分析

Pooled rates of adenoma detection by colonoscopy in asymptomatic average-risk individuals with positive fecal immunochemical test: a systematic review and meta-analysis.
PubMed 文献 · Gastrointest Endosc · 2022-04-09

FIT阳性者结肠镜汇总腺瘤检出率(ADR)为47.8%(95%CI 44.1-51.6),男性58.3%、女性41.9%,支持现行FIT阳性结肠镜ADR基准(男性≥45%、女性≥35%)。

要点

  • FIT阳性人群结肠镜汇总ADR为47.8%,支持现行男性≥45%、女性≥35%的基准。
  • 汇总晚期ADR为25.3%,结直肠癌检出率为5.1%。
  • 定性FIT评估、1份粪便样本、阈值100 ng血红蛋白/mL时ADR参数表现优良。

核心结论

  • 该Meta分析支持现行FIT阳性个体结肠镜ADR基准。
  • 定性评估1份粪便样本、检测阈值100 ng血红蛋白/mL时展示出优良的汇总ADR参数,且每位内镜医师的ADR随时间改善。

研究设计与样本

  • 系统综述与Meta分析,检索PubMed、EMBASE和Web of Science(2021年10月),采用随机效应模型,异质性用I²和95%预测区间评估。

主要发现

  • 汇总FIT筛查率为69.8%(95%CI 62.8-76.1),汇总FIT阳性率为5.4%(95%CI 4.3-6.9),结肠镜完成率为85%(95%CI 82.8-86.9)。
  • 汇总ADR为47.8%(95%CI 44.1-51.6),汇总晚期ADR为25.3%(95%CI 22-29),汇总结直肠癌检出率为5.1%(95%CI 4.4-5.9)。
  • 男性汇总ADR为58.3%(95%CI 52.8-63.6),女性为41.9%(95%CI 36.4-47.6)。
  • 定性FIT评估的汇总ADR为67.7%(95%CI 50.7-81),1份粪便样本FIT为52.8%(95%CI 48.8-56.8),阈值100 ng血红蛋白/mL为52.1%(95%CI 47-57.1)。
  • 基于时间段的累积分析显示,ADR随时间从30.5%(95%CI 24.6-37.2)改善至47.8%(95%CI 44.1-51.6)。

关键数值与推荐

  • 现行FIT阳性结肠镜ADR基准为男性≥45%、女性≥35%,原文指出其基于薄弱、低质量证据。
  • 本Meta分析汇总ADR为47.8%(95%CI 44.1-51.6),支持上述基准。
  • 定性FIT评估的汇总ADR为67.7%(95%CI 50.7-81),1份粪便样本FIT为52.8%(95%CI 48.8-56.8),阈值100 ng血红蛋白/mL为52.1%(95%CI 47-57.1)。

临床怎么用

  • 原文结论为:该Meta分析支持现行FIT阳性个体结肠镜ADR基准。
  • 原文指出定性评估1份粪便样本、检测阈值100 ng血红蛋白/mL时展示出优良的汇总ADR参数。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Current adenoma detection rate (ADR) benchmarks for colonoscopy in individuals positive for a fecal immunochemical test (FIT) are ≥45% in men and ≥35% in women. These are based on weak, low-quality evidence. We performed a meta-analysis to ascertain the pooled ADR in FIT-positive colonoscopy. METHODS: Major databases like PubMed, EMBASE, and Web of Science were searched in October 2021 for studies reporting on ADR of colonoscopy in a FIT-positive population. Meta-analysis was performed by standard methodology using the random-effects model. Heterogeneity was assessed by I2 and 95% prediction interval statistics. RESULTS: Thirty-four high-quality studies that included more than 6 million asymptomatic average-risk individuals were analyzed; 2,655,345 individuals completed a screening FIT test. The pooled FIT screening rate was 69.8% (95% CI, 62.8-76.1), the pooled FIT positivity rate was 5.4% (95% CI, 4.3-6.9), and the colonoscopy completion rate was 85% (95% CI, 82.8-86.9). The pooled ADR was 47.8% (95% CI, 44.1-51.6), pooled advanced ADR was 25.3% (95% CI, 22-29), and the pooled colorectal cancer detection rate was 5.1% (95% CI, 4.4-5.9). The pooled ADR in men was 58.3% (95% CI, 52.8-63.6) and in women was 41.9% (95% CI, 36.4-47.6). The pooled ADR with qualitative FIT assessment was 67.7% (95% CI, 50.7-81), with 1-stool sample FIT was 52.8% (95% CI, 48.8-56.8), and at a cutoff threshold of 100 ng hemoglobin/mL was 52.1% (95% CI, 47-57.1). Based on time-period cumulative analysis, the ADR improved over time from 30.5% (95% CI, 24.6-37.2) to 47.8% (95% CI, 44.1-51.6). CONCLUSIONS: This meta-analysis supports the current ADR benchmarks for colonoscopy in FIT-positive individuals. Excellent pooled ADR parameters were demonstrated with qualitative assessment of 1 stool sample at a test cutoff value of 100 ng hemoglobin/mL, and ADR per endoscopist improved over time.

来源:Gastrointest Endosc,查看原文。版权归原作者所有。

引用

  1. Mohan BP, Khan SR, Daugherty E, et al. Pooled rates of adenoma detection by colonoscopy in asymptomatic average-risk individuals with positive fecal immunochemical test: a systematic review and meta-analysis. Gastrointest Endosc. 2022. PMID: 35413330. doi:10.1016/j.gie.2022.04.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。